X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

ChargePoint Technology appoins new COO to drive future growth

Content Team by Content Team
19th November 2021
in News
ChargePoint Technology appoins new COO to drive future growth

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Powder containment and aseptic processing specialist, ChargePoint Technology, has welcomed Gary Lynch as Chief Operating Officer (COO). Gary’s appointment will see him drive the future growth of the company, managing and further improving operations to enhance efficiency. ChargePoint Technology will continue to adapt to the industry’s changing needs and Gary’s role will facilitate its new ventures into the latest technologies.

As part of his future goals for the company, he will focus on working closely with the team in scaling its services while maintaining operational efficiency and fulfilling customer requirements. By nurturing talent within the business, Gary will help drive the company’s growth plans.

Gary joins ChargePoint Technology from Harvard Technology, a lighting solutions manufacturer, where he acted as CEO for the company. During his time in the role, Gary implemented the return of manufacturing operations to the UK from overseas, driving significant increases in revenue as well as transforming the company’s product portfolio.

Prior to Harvard Technology, Gary held senior positions at GE Power Conversion, Nikon Metrology and Mobilis Healthcare Group, where he bolstered his expertise across the manufacturing, supply chain and pharmaceutical industries.

Speaking about his appointment, Gary commented: “I am absolutely delighted to join ChargePoint Technology and I am looking forward to working with the team, who have shown great success in supporting the pharma industry.

“I’m joining as COO at an exciting time for the company and the sector. As part of my role, I look forward to working with the team to drive the operations within the business, to support in the delivery of the next stages of our business strategy.”

Chris Eccles, Chief Executive Officer (CEO) at ChargePoint Technology added: “Gary will be a fantastic asset to the team and will drive our growth ambitions we have for the business. Gary’s appointment comes ahead of our expansion across all our platforms as well as bringing operations to best in class. It will enable us to focus on more of the strategic elements and priorities for the business and deliver our ambitious growth plans.”

Previous Post

Beximco Pharma introduces world's first generic molnupiravir, an oral antiviral drug for COVID-19 treatment

Next Post

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Next Post
First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In